Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991248 | 0.89 | BRD4 (0.76) | BRD4L3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL29694632 | 0.89 | BRD4 (0.76) | BRD4L3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL13818079 | 0.88 | BRD4 (0.66) | BRD4L3MBTL1KMT2AALDH1A1LMNA | |
| SCHEMBL22275075 | 0.82 | HSD17B10 (0.63) | BRD4L3MBTL1KMT2AALDH1A1LMNA | |
| SCHEMBL30101903 | 0.82 | HSD17B10 (0.63) | BRD4L3MBTL1KMT2AALDH1A1LMNA | |
| SCHEMBL8692725 | 0.82 | BRD4 (0.58) | BRD4KMT2AALDH1A1LMNAMAPK10 | |
| SCHEMBL28751799 | 0.81 | BRD4 (0.56) | BRD4L3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL1169159 | 0.81 | BRD4 (0.56) | BRD4L3MBTL1KMT2AALDH1A1LMNA | |
| SCHEMBL1894761 | 0.78 | L3MBTL1 (0.58) | BRD4L3MBTL1ALDH1A1KDM4EPOLB | |
| SCHEMBL12605100 | 0.78 | BRD4 (0.53) | BRD4L3MBTL1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279487-B2 | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279487-B2 | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279487-B2 | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1467970-B1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1467970-B1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1467970-A4 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050119482-A1 | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
| EP-1467970-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062204-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119482-A1 | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | HCLS1, POLR2A, CCNT1 | BRD4 895/4885L3MBTL1 175/4885KMT2A 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.